A Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of HS-10506 in Healthy Subjects
Latest Information Update: 26 Jul 2023
At a glance
- Drugs HS 10506 (Primary)
- Indications Depressive disorders; Insomnia
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 26 Jul 2023 New trial record